Chargement en cours...
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19
Given the speed of viral infection spread, repurposing of existing drugs has been given the highest priority in combating the ongoing COVID-19 pandemic. Only drugs that are already registered or close to registration, and therefore have passed lengthy safety assessments, have a chance to be tested i...
Enregistré dans:
| Publié dans: | Biomed Pharmacother |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Author(s). Published by Elsevier Masson SAS.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7392152/ https://ncbi.nlm.nih.gov/pubmed/32763818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biopha.2020.110582 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|